Last update
3/22/2026
Reviewed By
Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 14 Researches
7.9
USERS' SCORE
Good
Based on 1 Review
8.1
Supplement Facts
Serving Size: 2 Capsules
Amount Per Serving
%DV
Vitamin E (as d-α-tocopheryl succinate)
126 mg
840%
Aged Garlic Extract™†† Powder (bulb)
600 mg
**
Hawthorn Berry (fruit)
100 mg
**
Cayenne Pepper (fruit)
20 mg
**
Top Medical Research Studies
9
We investigated the effects of a daily dose of 300 mg vitamin E for treating metabolic dysfunction-associated steatohepatitis (MASH). In our study, 124 non-diabetic individuals were randomly assigned to either vitamin E or a placebo.
The results showed that 29.3% of those on vitamin E had improvements in liver histology, compared to just 14.1% in the placebo group. While we saw significant benefits in liver conditions like steatosis and inflammation, 12 serious adverse events were reported, although they weren’t linked to the treatment.
Overall, our findings indicate that vitamin E may offer meaningful improvements in liver health for those with MASH.
The results showed that 29.3% of those on vitamin E had improvements in liver histology, compared to just 14.1% in the placebo group. While we saw significant benefits in liver conditions like steatosis and inflammation, 12 serious adverse events were reported, although they weren’t linked to the treatment.
Overall, our findings indicate that vitamin E may offer meaningful improvements in liver health for those with MASH.
Read More
9
We analyzed multiple clinical trials to understand how vitamin E impacts liver disease, specifically metabolic dysfunction-associated steatotic liver disease (MASLD).
Our findings reveal that vitamin E significantly improves key liver markers like alanine aminotransferase (ALT) and aspartate aminotransferase (AST), suggesting it may help reduce liver inflammation.
Additionally, vitamin E enhances liver histology by decreasing fat accumulation and inflammation. However, it does not appear to affect liver fibrosis.
Overall, vitamin E could be a valuable option for managing liver health in MASLD patients.
Our findings reveal that vitamin E significantly improves key liver markers like alanine aminotransferase (ALT) and aspartate aminotransferase (AST), suggesting it may help reduce liver inflammation.
Additionally, vitamin E enhances liver histology by decreasing fat accumulation and inflammation. However, it does not appear to affect liver fibrosis.
Overall, vitamin E could be a valuable option for managing liver health in MASLD patients.
Read More
9
We examined how vitamin E supplementation affects liver disease in children with Gaucher disease. In this clinical trial, 40 pediatric patients receiving enzyme replacement therapy were divided into two groups: one received vitamin E for six months and the other did not.
The results showed that vitamin E significantly reduced oxidative stress markers and improved liver health, as indicated by decreases in liver and spleen volumes and stiffness. This suggests that vitamin E can enhance treatment efficacy for Gaucher disease, making it a safe and beneficial addition to existing therapies.
The results showed that vitamin E significantly reduced oxidative stress markers and improved liver health, as indicated by decreases in liver and spleen volumes and stiffness. This suggests that vitamin E can enhance treatment efficacy for Gaucher disease, making it a safe and beneficial addition to existing therapies.
Read More
Most Useful Reviews
4
Complicated recovery
51 people found this helpful
CAUTION!!! I have multiple health issues from having liver disease, currently recovering from stage 3 liver disease. One notable side effect has been severe heart problems, including palpitations. I tried this product hoping it would help with thrombosis and liver health, but I experienced terrible headaches and increased heart palpitations. After four days, I suffered from significant nosebleeds. Beware of high vitamin E content; it may elevate heart disease risks. I've found that beetroot and omega-3 work better for my condition.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 14 Researches
7.9
- All Researches
9
We investigated the effects of a daily dose of 300 mg vitamin E for treating metabolic dysfunction-associated steatohepatitis (MASH). In our study, 124 non-diabetic individuals were randomly assigned to either vitamin E or a placebo.
The results showed that 29.3% of those on vitamin E had improvements in liver histology, compared to just 14.1% in the placebo group. While we saw significant benefits in liver conditions like steatosis and inflammation, 12 serious adverse events were reported, although they weren’t linked to the treatment.
Overall, our findings indicate that vitamin E may offer meaningful improvements in liver health for those with MASH.
The results showed that 29.3% of those on vitamin E had improvements in liver histology, compared to just 14.1% in the placebo group. While we saw significant benefits in liver conditions like steatosis and inflammation, 12 serious adverse events were reported, although they weren’t linked to the treatment.
Overall, our findings indicate that vitamin E may offer meaningful improvements in liver health for those with MASH.
Read More
9
We examined how vitamin E supplementation affects liver disease in children with Gaucher disease. In this clinical trial, 40 pediatric patients receiving enzyme replacement therapy were divided into two groups: one received vitamin E for six months and the other did not.
The results showed that vitamin E significantly reduced oxidative stress markers and improved liver health, as indicated by decreases in liver and spleen volumes and stiffness. This suggests that vitamin E can enhance treatment efficacy for Gaucher disease, making it a safe and beneficial addition to existing therapies.
The results showed that vitamin E significantly reduced oxidative stress markers and improved liver health, as indicated by decreases in liver and spleen volumes and stiffness. This suggests that vitamin E can enhance treatment efficacy for Gaucher disease, making it a safe and beneficial addition to existing therapies.
Read More
9
We analyzed multiple clinical trials to understand how vitamin E impacts liver disease, specifically metabolic dysfunction-associated steatotic liver disease (MASLD).
Our findings reveal that vitamin E significantly improves key liver markers like alanine aminotransferase (ALT) and aspartate aminotransferase (AST), suggesting it may help reduce liver inflammation.
Additionally, vitamin E enhances liver histology by decreasing fat accumulation and inflammation. However, it does not appear to affect liver fibrosis.
Overall, vitamin E could be a valuable option for managing liver health in MASLD patients.
Our findings reveal that vitamin E significantly improves key liver markers like alanine aminotransferase (ALT) and aspartate aminotransferase (AST), suggesting it may help reduce liver inflammation.
Additionally, vitamin E enhances liver histology by decreasing fat accumulation and inflammation. However, it does not appear to affect liver fibrosis.
Overall, vitamin E could be a valuable option for managing liver health in MASLD patients.
Read More
9
We investigated how gamma-tocotrienol (γ-T3), a form of vitamin E, impacts the growth of liver cancer cells. Our study involved treating HepG2 cells, which overexpress a specific protein (HSD17B4), with vitamin E and watching how it changes their behavior.
We found that γ-T3 not only slowed down cell growth but also promoted cell death in these problematic liver cells. Importantly, the effect was not due to changing HSD17B4 expression directly, but by inhibiting its activity instead.
Overall, our results suggest that γ-T3 could be a promising treatment option for liver cancer, especially in targeting cancer growth pathways.
We found that γ-T3 not only slowed down cell growth but also promoted cell death in these problematic liver cells. Importantly, the effect was not due to changing HSD17B4 expression directly, but by inhibiting its activity instead.
Overall, our results suggest that γ-T3 could be a promising treatment option for liver cancer, especially in targeting cancer growth pathways.
Read More
8
We investigated the link between dietary antioxidants, including vitamin E, and the risk of liver fibrosis in people who had gallbladder surgery. Analyzing data from 773 participants, we calculated the composite dietary antioxidant index, which showed a negative association with hepatic fibrosis risk.
The results revealed that higher antioxidant intake, particularly vitamin E, was related to a reduced risk of liver fibrosis. However, there wasn’t a significant impact observed on metabolic dysfunction-associated fatty liver disease. Overall, our findings suggest that boosting antioxidant intake could help protect the liver.
The results revealed that higher antioxidant intake, particularly vitamin E, was related to a reduced risk of liver fibrosis. However, there wasn’t a significant impact observed on metabolic dysfunction-associated fatty liver disease. Overall, our findings suggest that boosting antioxidant intake could help protect the liver.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.1
- All Reviews
- Positive Reviews
- Negative Reviews
4
Complicated recovery
51 people found this helpful
CAUTION!!! I have multiple health issues from having liver disease, currently recovering from stage 3 liver disease. One notable side effect has been severe heart problems, including palpitations. I tried this product hoping it would help with thrombosis and liver health, but I experienced terrible headaches and increased heart palpitations. After four days, I suffered from significant nosebleeds. Beware of high vitamin E content; it may elevate heart disease risks. I've found that beetroot and omega-3 work better for my condition.
Read More
Frequently Asked Questions
No FAQs are available for this product and symptom.
References
- Hua S, Zhong W, Sha Y, Ma M, Ge S. Negative association of composite dietary antioxidant index with risk of hepatic fibrosis in individuals underwent cholecystectomy: a cross-sectional study. Sci Rep. 2025;15:9040. 10.1038/s41598-025-93782-z
- Song Y, Ni W, Zheng M, Sheng H, Wang J, et al. Vitamin E (300 mg) in the treatment of MASH: A multi-center, randomized, double-blind, placebo-controlled study. Cell Rep Med. 2025;6:101939. 10.1016/j.xcrm.2025.101939
- Palencia-Campos A, Ruiz-Cañas L, Abal-Sanisidro M, López-Gil JC, Batres-Ramos S, et al. Reprogramming tumor-associated macrophages with lipid nanosystems reduces PDAC tumor burden and liver metastasis. J Nanobiotechnology. 2024;22:795. 10.1186/s12951-024-03010-5
- Dong JX, Jiang LL, Liu YP, Zheng AX. Association between composite dietary antioxidant index and metabolic dysfunction-associated fatty liver disease: a cross-sectional study from NHANES. BMC Gastroenterol. 2024;24:465. 10.1186/s12876-024-03556-6
- Sahin A, Demirel-Yalciner T, Sozen E, Ozer NK. Protective effect of alpha-tocopherol on lipogenesis and oxysterol production in hypercholesterolemia-induced nonalcoholic steatohepatitis. Free Radic Res. 2024;58:630. 10.1080/10715762.2024.2421173
- Wen H, Deng H, Yang L, Li L, Lin J, et al. Vitamin E for people with non-alcoholic fatty liver disease. Cochrane Database Syst Rev. 2024;10:CD015033. 10.1002/14651858.CD015033.pub2
- Adly AAM, Ismail EAR, Ibrahim FA, Atef M, El Sayed KA, et al. A 6-month randomized controlled trial for vitamin E supplementation in pediatric patients with Gaucher disease: Effect on oxidative stress, disease severity and hepatic complications. J Inherit Metab Dis. 2025;48:e12792. 10.1002/jimd.12792
- Al-Baiaty FDR, Ishak S, Mohd Zaki F, Masra F, Abdul Aziz DA, et al. Assessing the efficacy of tocotrienol-rich fraction vitamin E in obese children with non-alcoholic fatty liver disease: a single-blind, randomized clinical trial. BMC Pediatr. 2024;24:529. 10.1186/s12887-024-04993-8
- Chee NM, Sinnanaidu RP, Chan WK. Vitamin E improves serum markers and histology in adults with metabolic dysfunction-associated steatotic liver disease: Systematic review and meta-analysis. J Gastroenterol Hepatol. 2024;39:2545. 10.1111/jgh.16723
- Li J, Yang Y, Huang J, Ye D, Sun X, et al. A Comprehensive Investigation of Dietary Micronutrient Intakes and Risk of Alcoholic Liver Disease. J Nutr. 2024;154:2909. 10.1016/j.tjnut.2024.07.012
- Wang X, Liang X, Zhang N, Wang Y, Hu M, et al. Gamma-tocotrienol Inhibits Proliferation and Growth of HSD17B4 Overexpressing HepG2 Liver Cancer Cells. Curr Cancer Drug Targets. 2025;25:170. 10.2174/0115680096319171240623091614
- Albert SG, Wood EM. FIB-4 as a screening and disease monitoring method in pre-fibrotic stages of metabolic dysfunction-associated fatty liver disease (MASLD). J Diabetes Complications. 2024;38:108777. 10.1016/j.jdiacomp.2024.108777
- Akman AU, Erisgin Z, Turedi S, Tekelioglu Y. Methotrexate-induced hepatotoxicity in rats and the therapeutic properties of vitamin E: a histopathologic and flowcytometric research. Clin Exp Hepatol. 2023;9:359. 10.5114/ceh.2023.132251
- Malandris K, Papandreou S, Vasilakou D, Kakotrichi P, Sarakapina A, et al. Efficacy of pharmacologic interventions on magnetic resonance imaging biomarkers in patients with nonalcoholic fatty liver disease: systematic review and network meta-analysis. J Gastroenterol Hepatol. 2024;39:1219. 10.1111/jgh.16559
Data last updated:
